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Selective targeting of IL-2 to NKG2D bearing
cells for improved immunotherapy
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Despite over 20 years of clinical use, IL-2 has not fulfilled expectations as a safe and effective
form of tumour immunotherapy. Expression of the high affinity IL-2Ra chain on regulatory
T cells mitigates the anti-tumour immune response and its expression on vascular
endothelium is responsible for life threatening complications such as diffuse capillary leak and
pulmonary oedema. Here we describe the development of a recombinant fusion protein
comprised of a cowpox virus encoded NKG2D binding protein (OMCP) and a mutated form
of IL-2 with poor affinity for IL-2Ra. This fusion protein (OMCP-mutIL-2) potently and
selectively activates IL-2 signalling only on NKG2D-bearing cells, such as natural killer (NK)
cells, without broadly activating IL-2Ra-bearing cells. OMCP-mutIL-2 provides superior
tumour control in several mouse models of malignancy and is not limited by mouse
strain-specific variability of NK function. In addition, OMCP-mutIL-2 lacks the toxicity and
vascular complications associated with parental wild-type IL-2.
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T
he IL-2Ra chain serves to capture IL-2 at the cell surface to
facilitate subsequent binding to the signalling part of the
receptor, namely the IL-2Rbg chains. Resting cytotoxic
lymphocytes, such as natural killer (NK) and CD8þ T cells, are
believed to express little to no IL-2Ra at the cell surface and are
thus not activated by low-dose IL-2 (ref. 1). IL-2Ra expression on
these cells increases after initial activation and is required for
maximum cytotoxic lymphocyte expansion2. High dose IL-2 can
activate even resting cytotoxic lymphocytes, and is thus approved
for treatment of several malignancies3–5. Most patients do not
benefit from high dose IL-2 therapy, however, due to activation of
regulatory T cell (Tregs) and systemic complications of hemo-
dynamic instability, generalized capillary leak and end organ
failure due to activation of vascular endothelium3,6,7. Both
vascular endothelium and Tregs express IL-2Ra and are thus
preferentially activated by IL-2 over cytotoxic lymphocytes8.
Lowering the IL-2 dose can ameliorate side effects but also
decreases efficacy. Mutant forms of IL-2, such as those with
substitutions of alanine for arginine at the 38 position (R38A)
and/or lysine for phenylalanine at the 42 position (F42K),
decrease the affinity of IL-2 for IL-2Ra and thus eliminate many
side effects9. However, such IL-2a mutants also decrease the
efficacy of immunotherapy2. A form of IL-2 that could
preferentially activate cytotoxic lymphocytes in the absence of
IL-2Ra engagement would be highly advantageous for clinical
applications.
NKG2D is an activating receptor that is expressed on human NK
and CD8þ T cells, murine NK cells and activated murine CD8þ
T cells10. NKG2D recognizes MHC class-I-like stress ligands
expressed on the surface of malignant or virally-transformed cells11.
Consequently, many tumours and virally infected cells seek to
counteract NKG2D-based immunity12,13. Orthopoxvirus major
histocompatibility complex class I-like protein, or OMCP, is a
small NKG2D binding protein secreted by monkeypox and cowpox
virus infected cells. There are no OMCP related proteins encoded
by current orthopoxvirus vaccine strains and thus there is very
limited exposure in humans. OMCP binds both human and murine
NKG2D with an affinity equal to, or greater than, all other known
NKG2D ligands14,15. Therefore, OMCP could serve as an ideal
targeting vector to deliver IL-2 specifically to cytotoxic lymphocytes.
Here we describe the engineering of a fusion protein comprised of
OMCP linked to an IL-2 variant with diminished IL-2Ra binding.
This fusion construct retains the safety profile of IL-2 mutants with
reduced IL-2Ra reactivity while improving NK cell expansion
10-fold compared with wild-type IL-2. Systemic administration
decreases the growth and viability of both solid and liquid tumours
and significantly improves animal survival. We thus describe a safe
and efficacious IL-2 fusion protein that overcomes barriers
associated with standard high-dose IL-2 therapy.
Results
OMCP-mutIL-2 activates cytotoxic lymphocytes in vitro. We
designed an IL-2 fusion protein combining the high affinity
NKG2D ligand OMCP with an IL-2 mutated to reduce IL-2Ra
reactivity (mutIL-2). Our construct, termed OMCP-mutIL-2,
consists of the 152 residue OMCP protein fused to the N-ter-
minus of the 133 amino acid R38A/F42K mutant form of human
IL-2 (mutIL-2) via a flexible 30 residue linker (Fig. 1a,b). We
incubated equimolar concentration of biotinylated wild-type IL-2
(wtIL-2), mutIL-2 or OMCP-mutIL-2 with C57BL/6
splenocytes at 4 C in vitro and compared binding flow cytome-
trically. The addition of the OMCP to mutIL-2 increased
the retention of the fusion protein to NK cells compared with
mutIL-2 or wtIL-2 (Fig. 1c left panel) as evidenced by
significantly higher MFI. This increase in lymphocyte binding
depended on functional and reactive NKG2D, as competitive
preincubation of splenocytes with free monomeric OMCP
eliminated enhanced binding of OMCP-mutIL-2 to NK cells
(Fig. 1c middle panel). Consistent with this no increase in
OMCP-mutIL-2 binding over mutIL-2 was evident in NK
cells from C57BL/6NKG2D / mice (Fig. 1c right panel). No
increased binding of OMCP-mutIL-2 over mutIL-2 was evident
for either wild-type or C57BL/6NKG2D / B or T lymphocytes
(Supplementary Fig. 1). Taken together our data demonstrate that
a fusion protein consisting of a cytokine and an NKG2D ligand
may have utility for targeting NKG2D expressing lymphocytes
such as NK cells.
Based on this data we next set out to examine the efficacy of
OMCP-mutIL-2 in activation of NK cells from two different
strains of mice (A/J and C57BL/6) with poor and robust NK
function, respectively16. Compared with wtIL-2 or mutIL-2,
OMCP-mutIL-2 strongly upregulated CD69 on NK cells of both
strains after a two-day co-culture with 100 IUeml 1 of
cytokine (Fig. 2a left panel; Supplementary Fig. 2a). Hundred
fold higher concentrations of wtIL-2 or mutIL-2 induced
similar increases in CD69 expression compared with OMCP-
mutIL-2 (Supplementary Fig. 2b). CD8þ T cells demonstrated
no upregulation of CD69 (Fig. 2a middle panel). This is
consistent with the low surface expression of IL-2 receptors and
NKG2D on unactivated, resting murine T lymphocytes.
Activation of CD4þFoxp3þ Tregs, as measured by upregu-
lation of ICOS, was evident after co-culture with wtIL-2, but
not with mutIL-2 nor OMCP-mutIL-2 (Fig. 2a right panel).
While CD69 upregulation is only a transient marker of
lymphocyte activation, acquisition of cytotoxic mediators
such as perforin has been described as a reliable measure
of cytotoxicity17. To expand our murine observations we
co-cultured freshly isolated human peripheral blood
lymphocytes (PBLs) with 100 IUeml 1 of OMCP-mutIL-2,
wtIL-2 or mutIL-2 in a similar manner to murine splenocytes
and evaluated intracellular perforin accumulation flow
cytometrically. Consistent with murine CD69 data, human
NK cells treated with OMCP-mutIL-2 had higher perforin
levels than those treated with wild-type IL-2, mutIL-2 or saline
(Fig. 2b left panel). Thus, exposure to OMCP-mutIL-2 results in
preferential activation of human NK cells as well. Limited
activation of CD8þ T cells was evident with any of the
constructs (Fig. 2b middle panel) and human Tregs were
preferentially activated by wtIL-2 but not mutIL-2 or OMCP-
mutIL-2 similar to mice (Fig. 2b right panel).
Significant proliferation of both C57BL/6 NK and CD8þ
T cells was evident in vitro after incubation with 1000 IUeml 1
of wtIL-2 and OMCP-mutIL-2 but not mutIL-2 (Fig. 2c left and
middle panel) whereas CD4þFoxp3þ Tregs proliferated only
with wtIL-2 (Fig. 2c right panel). Interestingly, in human
peripheral blood mononuclear cells (PBMC), derived from
CMV-seropositive donors, in vitro stimulation with a CMV
pp65 peptide in the presence of 100 IUeml 1 wtIL-2 and
OMCP-mutIL-2 led to antigen (pp65)-specific CD8þ T cells
expansion (Supplementary Fig. 2c). Furthermore OMCP-mutIL-2
activation of C57BL/6 CD8þ T cells and NK cells was equivalent
to mutIL-2 in NKG2D / splenocytes, supporting the impor-
tance of NKG2D targeting for the superior effectiveness of
OMCP-mutIL-2 (Fig. 2d; Supplementary Fig. 2d). Taken together
these data indicate that exposure to OMCP-mutIL-2 results in
preferential NK activation in vitro, that is superior or equivalent
to wtIL-2 in a dose-dependent manner without concomitant Treg
activation. While CD8þ T cells require longer exposure to higher
doses for activation, or concomitant T cell receptor stimulation
with a relevant peptide, OMCP-mutIL-2 is able to activate them
at a comparable level to wtIL-2.
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OMCP-mutIL-2 offers a favourable safety profile in vivo. Dose-
dependent toxicity can limit cytokine administration in vivo18.
While A/J mice tolerated 750,000 IUe of wtIL-2, mortality was
evident at higher doses (Fig. 3a). Even at the 750,000 IUe dose,
mice demonstrated distress, weight loss, decreased food
consumption, ascites and hepatic inflammation (Fig. 3a–c and
Supplementary Fig. 3a). These side-effects resemble the capillary
leakage and clinical distress associated with high dose IL-2
therapy in humans7. Depletion of NK cells through the
administration of anti-Asialo-GM1 ameliorated mortality, but
not weight loss, induced by high dose wtIL-2 (1,500,000 IUe) in
A/J mice. This confirmed that side effects of wtIL-2 can occur
independent of NK cells (Fig. 3d). Unlike with wtIL-2 no animal
death was evident after high dose OMCP-mutIL-2 or mutIL-2
treatment in the presence or absence of NK cells. Animal weight
loss after administration of high dose OMCP-mutIL-2 occurred
only in NK cell-sufficient mice, suggesting that toxicity of
this fusion protein was solely due to immunoactivation (Fig. 3d).
A regimen of low-dose, 200,000 IUe of wtIL-2, mutIL-2 or
OMCP-mutIL-2, was well tolerated in A/J mice with minimal
weight loss, distress or organ inflammation (Fig. 3e–g). Capillary
leak, however, was still evident at this dosing regimen for wtIL-2
(Fig. 3f). C57BL/6 mice were able to tolerate higher doses of wtIL-
2 but still suffered significant morbidity when administered a
regimen equivalent to or higher than 750,000 IUe (Supplementary
Fig. 3b). Interestingly weight loss was ameliorated in
C57BL/6NKG2D / mice treated with OMCP-mutIL-2, consis-
tent with the importance of NKG2D for immunoactivation by
our fusion protein (Supplementary Fig. 3c). Taken together these
data show that OMCP-mutIL-2 offers a safety advantage
compared with wtIL-2.
OMCP-mutIL-2 expands and activates NK Cells in vivo. When
A/J mice received a regimen of 200,000 IUe of cytokine or fusion
protein, given as 10 equal doses over 5 days, both wtIL-2 and
OMCP-mutIL-2 increased splenocyte numbers compared
with saline-treated controls (Fig. 4a). OMCP-mutIL-2 led to a
substantial expansion and activation of NK cells as measured by
cell number and surface KLRG1 levels (Fig. 4b). Remarkably, in
OMCP-mutIL-2 treated mice, NK cells comprised close to half of
all splenic lymphocytes, paralleling or even surpassing the
total lymphocyte counts of saline or mutIL-2-treated mice
(Fig. 4a versus b). NK cell expansion by 200,000 IUe of
OMCP-mutIL-2 was greater than that seen with near toxic doses
of wtIL-2 (750,000 IU), high dose mutIL-2 (3,500,000 IUe) or
wtIL-2 complexed to anti-IL-2 antibody (clone MAB602)19
(Fig. 4b). Superior expansion of NK cells by OMCP-mutIL-2
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Figure 1 | Generation of OMCP-mutIL-2. (a) Schematic structure of OMCP-mutIL-2. (b) Molecular mass of OMCP-mutIL-2 compared with mutIL-2 and
wild-type IL-2 by Coomassie staining. wt IL-2, mutIL-2 and OMCP-mutIL-2 were produced in FreeStyle 293-F cells and purified from supernatants by
Ni-NTA chromatography. The proteins have higher molecular mass due to glycosylation. The lower migrating band for mutIL-2 corresponds to
unglycosylated protein. Based on differences in molecular mass all cytokines and construct were administered on a molar basis with 1 ml of 4.4 mM solution
defined as 1000 IU equivalents (IUe) throughout the manuscript. This effectively allows for equimolar comparison between wt IL-2, mutIL-2 and OMCP-
mutIL-2 despite different molecular mass. (c) Binding of various biotin-labelled cytokines and constructs to wild-type C57BL/6 splenic NK cells without
(left panel) or with (middle panel) preincubation with OMCP. Binding of biotin-labelled cytokines and constructs to C57BL/6NKG2D/ NK cells (right
panel). As described in the methods spleen cells were co-cultured with equimolar concentration of biotinylated cytokines and fusion construct at 4 C
followed by labelling with phycoerythrin (PE) conjugated streptavidin and mixed fluorochrome-conjugated antibodies for defining of NK cells. Data were
acquired flow cytometrically and is representative of three separate experiments with MFI comparison of PE-labelled constructs on NK cells (viable,
NK1.1þ , CD3 , CD19 ). Data analysis performed by ANOVA for multiple comparisons and unpaired t-test for individual comparisons and shown as
mean±s.e.m. All bar graphs represent mean±s.e.m. ns P40.05; *Po0.05; black¼ saline; blue¼wtIL-2, red¼OMCP-mutIL-2, green¼mutIL-2.
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was even possible at doses 2-fold lower than wtIL-2
(Supplementary Fig. 4a). Furthermore, a mutIL-2 fusion protein
comprised of a different NKG2D ligand with a B500-fold lower
affinity, ULBP3 (ref. 15), did not significantly expand NK
cells but still offered superior activation compared with
mutIL-2 alone (Supplementary Fig. 4a). No significant increase
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Figure 2 | In vitro evaluation of OMCP-mutIL-2. (a) In vitro flow cytometrically evaluated activation of A/J spleen-derived lymphocyte subsets after 36 h of
culture in 100 IUe ml 1 of cytokines or OMCP-mutIL-2 construct. Graph demonstrating one representative histogram plot and median fluorescent intensity
(MFI) ±s.e.m. across 5–7 separate experiments, containing one to two mice per group per experiment, as a graph in right upper corner. (b) In vitro
activation of human peripheral blood lymphocyte subsets after 36 h of culture in 100 IUe ml 1 of cytokines or OMCP-mutIL-2 construct. Graph
demonstrating one representative histogram plot and MFI±s.e.m. across 4–5 separate experiments as graph in right upper corner. Proliferation of C57BL/6
wild-type (c) or C57BL/6NKG2D/ (d) splenic lymphocyte subsets after 5-day culture in 1,000 IUeml 1 of cytokines or OMCP-mutIL-2. Graph
demonstrating one representative histogram plot of four separate experiments. Composite MFI±s.e.m. shown as graph below the CFSE histogram plots.
Comparison of MFI performed by ANOVA for multiple comparisons and unpaired t-test for each individual group. ns P40.05; *Po0.05; **Po0.01;
***Po0.001; black¼ saline; blue¼wtIL-2, red¼OMCP-mutIL-2, green¼mutIL-2.
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in CD4þFoxp3 or CD8þ T lymphocytes was evident in A/J
mice after wtIL-2 or OMCP-mutIL-2 treatment (Supplementary
Fig. 4b). Splenic DX5þCD3þ NKT cells, while lower in number
than DX5þCD3 NK cells, did expand after OMCP-mutIL-2
treatment, albeit equivalent to wtIL-2 in the A/J strain of mice
(Supplementary Fig. 4b).
In contrast to the A/J strain, C57BL/6 mice were able to
tolerate higher doses of IL-2 (Supplementary Fig. 3b). At higher
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Figure 3 | In vivo dosing of different forms of IL-2 in A/J Mice. (a) Animal mortality and morbidity, as assessed by survival (top) and weight loss
(bottom); (b) accumulation of ascites and pleural fluid (representative syringe; top; average from all mice in the group; bottom) and (c) tissue inflammation
after administration of wtIL-2 (arrows point to inflammatory infiltrates). All Hþ E figures presented at 200 exposure with scale bar at bottom
left¼ 100mm. (d) Animal mortality (top) and morbidity as assessed by weight loss (bottom) after administration of high dose wtIL-2 (left), OMCP-mutIL-2
(middle) and mutIL-2 (right) in anti-AsialoGM1 (solid line) or rabbit IgG-treated (dotted line) A/J mice. Weight loss compared by unpaired t-test at
each individual day between NK sufficient and depleted mice. Kaplan–Meier survival graphs compared by Log-rank (Mantel–Cox) test. (e) Weight loss,
(f) ascites (representative syringe-top; average from all mice in the group-bottom) and (g) organ inflammation in mice treated with 200,000 IUe of either
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doses of 750,000 IUe OMCP-mutIL-2 induced greater expansion
of NK cells compared with other cytokines, similar to that
described for A/J mice (Fig. 4c,d). Importantly, expansion of NK
cells was not evident in OMCP-mutIL-2 treated C57BL/
6NKG2D / mice, confirming the requirement for NKG2D for
the function of OMCP-mutIL-2 (Supplementary Fig. 4c).
Consistent with the A/J strain neither CD4þFoxp3 nor
CD8þ T lymphocytes expanded after treatment with OMCP-
mutIL-2 but DX5þCD3þ NKT cells did expand compared with
other cytokine therapy, consistent with their expression of
NKG2D (Supplementary Fig. 4d). Interestingly NKG2D reactivity
was still preserved in OMCP-mutIL-2-treated NK cells, as
measured by degranulation to plate-bound agonistic anti-NKG2D
antibody (clone A10)20 (Supplementary Fig. 4e). Thus, despite the
fact that OMCP is an NKG2D antagonist, the concentrations
needed for activation are not sufficient to significantly impede the
function of the NKG2D receptor.
OMCP-mutIL2 does not expand or activate Tregs. Preferential
activation of IL2Ra-expressing Tregs has been one of the main
challenges to IL-2 cytokine immunotherapy8. Consistent with this
notion wtIL-2 led to a significant expansion and activation of
CD4þFoxp3þTregs as measured by total cell number and
expression of ICOS, GITR, CD25 and KI-67 in A/J mice
(Fig. 5a). Expansion of this cell population was also evident
when wtIL-2 was complexed to anti-IL-2 antibodies (Fig. 5a)19.
Similar results were evident for the C57BL/6 strain except for the
ameliorated Treg expansion when wtIL-2 was complexed to anti-
IL-2 antibodies (Fig. 5b). However, for both strains of mice no
expansion or activation of Tregs was evident after treatment with
OMCP-mutIL-2 compared mutIL-2 or saline-treated controls
(Fig. 5a,b).
To test functional Treg-mediated suppression we treated
C57BL/6CD45.2þ mice expressing GFP on a Foxp3 promoter
(kindly provided by Chyi-Song Hseih) with saline, wtIL-2,
mutIL-2 or OMCP-mutIL-2 as described above. GFP-expressing
Tregs were isolated flow cytometrically and then co-cultured with
CFSE-labelled C57BL/6CD45.1þ congenic ‘responder’ T lympho-
cytes, activated by soluble anti-CD3 and T cell-depleted
splenocytes. Proliferation of responding T lymphocytes was
measured by dilution of CFSE in CD45.1þCD90.2þ T
lymphocytes. Only Tregs from wtIL-2-treated mice were able to
inhibit T cell proliferation confirming the phenotypic data and
further defining that treatment with OMCP-mutIL-2 does not
result in Treg activation (Fig. 5c). Furthermore, the NK/Treg ratio,
which has been described as a predictive factor for success of
immunotherapy21, was significantly increased in OMCP-mutIL-2
treated mice compared with all other conditions (Fig. 5d,e).
Taken together this data suggest that treatment with OMCP-
mutIL-2 offers a unique strategy for safe and efficacious NK
expansion in the absence of deleterious side effects or Treg
activation.
OMCP-mutIL-2 does not signal through NKG2D. To evaluate
IL-2 signalling we next quantitated STAT5 phosphorylation of
NK cells ex vivo. Lower levels of STAT5 phosphorylation were
evident in A/J compared with C57BL/6 NK cells at all
concentrations tested (Fig. 6a) suggesting that lymphocyte
dysfunction of A/J mice may partially result from inefficient
IL-2 signal transduction. Interestingly in such purified NK cell
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mice per group performed as 4–7 separate experiments for each strain of mice. Comparison performed by unpaired t-test between groups as indicated by
the lines. ns P40.05; *Po0.05; **Po0.01; ***Po0.001; black¼ saline; blue¼wtIL-2, red¼OMCP-mutIL-2, green¼mutIL-2, turkoise¼wtIL-2 complexed
to anti-IL-2.
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preparations wtIL-2 and OMCP-mutIL-2 demonstrated identical
dose-dependent STAT5 phosphorylation (Fig. 6a). In the absence
of NKG2D, OMCP-mutIL-2 failed to increase STAT5 phos-
phorylation over mutIL-2 alone (Fig. 6a). Taken together, these
data suggest that IL-2Ra engagement is important for peak IL-2
signalling even in resting NK cells, and that NKG2D-binding may
substitute for IL-2Ra-interaction in IL-2-mediated signal trans-
duction. Such data, however, opened the possibility that the
superior efficacy of OMCP-mutIL-2 over mutIL-2 alone was due
to concomitant signalling through NKG2D, since activation of
this receptor can act as a primary or co-stimulatory factor for NK
cells20.
Canonical dogma suggests that NKG2D signalling in resting
NK cells occurs through the Dap10/Vav/Grb2 pathway22, while
IL-2R signalling occurs through the Jak1/3/STAT5
pathway23(Fig. 6b). Nevertheless, alternative signalling pathways
have been described24. To evaluate more proximal signalling
events we compared Jak1 phosphorylation in the murine NKG2D
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expressing NK cell line Ky1.1 after incubation with wtIL-2,
mutIL-2 or OMCP-mutIL-2 (ref. 25). Consistent with phospho-
STAT-5 data, Jak1 phosphorylation was evident after exposure to
wtIL-2 and OMCP-mutIL-2 but not saline or mutIL-2 (Fig. 6c).
Since Vav controls NKG2D signalling in NK cells22 we next set
out to evaluate phosphorylation of this signalling intermediate as
a surrogate marker of NKG2D signalling. Since Ky1.1, as well as
other NK cell lines such as NK92, have a high level of constitutive
Vav phosphorylation (Supplementary Fig. 5) we evaluated
phospo-Vav levels in freshly isolated resting splenic C57BL/6
NK cells after a 15min exposure to cytokines. While a significant
increase in phospho-Vav was evident after NKG2D signalling
mediated by plate bound anti-NKG2D (clone A10), no increase in
Vav phosphorylation was evident after culture with OMCP-
mutIL-2, mutIL-2 or wtIL-2 (Fig. 6d). While this provided strong
evidence that OMCP-mutIL-2 signals through the IL-2R, we still
sought more rigorous data about the status of NKG2D signalling.
To study NKG2D signalling directly we took advantage
of a reductionist approach by utilizing DAP12-NFAT driven
b-galactosidase induction in BWZ.36 cells. As previously
described by us and others26,27 we co-expressed NKG2D along
with wild-type DAP12-GFP, or mutant non-signalling
DAP12Y2F-GFP, in the BWZ.36 cells which constitutively
expresses the IL2R common gamma chain (Fig. 6e). The
NKG2D/DAP12 expressing cells were then co-cultured with
either plate bound anti-NKG2D (clone A10), saline, wtIL-2,
mutIL-2 or OMCP-mutIL-2 at 1000 IUeml 1 or PMA
and ionomycin for 6 h. While plate bound anti-NKG2D and
PMA/ionomycin stimulation resulted in significant induction of
b-galactosidase activity in wild-type DAP12 expressing cells, no
such increased activity was evident in OMCP-mutIL-2 treated
cultures (Fig. 6f left panel). Consistent with the requirement for
NKG2D signalling no b-galactosidase induction was evident in
DAP12Y2F expressing mutants or parental BWZ.36 cells after
exposure to plate bound anti-NKG2D (Fig. 6f middle and right
panels). Taken together these data suggest that augmented NK
activation by OMCP-mutIL-2 is unlikely to be due to NKG2D
activation at physiological concentrations.
OMCP-mutIL-2 has a competitive advantage over wtIL-2.
Antibody-IL-2 complexes improve cytokine activity by extending
the duration of serum half-life28,29. To investigate whether the
linking of mutIL-2 to OMCP increased serum half-life we injected
500,000 IUe of fluorescently-labelled wtIL-2, mutIL-2 or OMCP-
mutIL-2 intravenously and monitored serum levels over time
with periodic blood draws. Whereas OMCP-mutIL-2 had a
slightly higher serum concentration at early time points, all
proteins were undetectable in the blood one hour post-injection
(Fig. 7a). This is shorter than the described 11–14 h serum half-
life of antibody-IL-2 conjugates28. Despite the injection of
identical amounts of cytokine, lower levels were detected in
C57BL/6 than A/J mice at all time points. Strain-specific
differences in the clearance of IL-2 may explain why C57BL/6
mice tolerate and require higher doses of IL-2 for NK expansion.
Nevertheless it is unlikely that prolonged circulation of the fusion
protein was responsible for the increased activation of NK cells by
OMCP-mutIL-2 in either strain.
IL-2 signalling results in the internalization of IL-2/IL-2R, with
subsequent degradation of IL-2 and IL-2Rbg30,31. The binding of
OMCP-mutIL-2 to both the IL-2 receptor and NKG2D could
possibly lead to altered internalization and thus enhance NK cell
activation by prolonging IL-2 signalling. To test this hypothesis,
we stimulated freshly isolated NK cells for 15min in vitro,
replaced the culture media with cytokine-free media, and
monitored STAT5 phosphorylation for four hours. Identical
decay of phospho-STAT5 was evident for both wtIL-2 and
OMCP-mutIL-2 (Fig. 7b). Thus, the superior activation of NK
cells by OMCP-mutIL-2 could not be explained by altered
duration of IL-2 signalling.
We next considered the possibility that the superior immuno-
logic effect of OMCP-mutIL-2 over wtIL-2 in vivo may be the
result of altered interaction with competing stromal cells (Fig. 7c).
Indeed, in the presence of other splenocytes OMCP-mutIL-2
demonstrated a dose-dependent enhancement in NK STAT5
phosphorylation compared with wtIL-2 (Fig. 7d). We next
explored the interplay between IL-2Ra reactivity of splenocytes
and NKG2D expression on NK cells in IL-2 signal transduction.
To accomplish this we isolated splenic NK cells from either
wild-type or NKG2D / C57BL/6 mice and combined them
with wild-type splenocytes depleted of NK cells in a 1:20 ratio
mirroring the E5% NK cell content in normal C57BL/6
splenocytes. Under such conditions STAT5 phosphorylation
was identical between NKG2D / and wild-type NK cells after
wtIL-2 stimulation (Fig. 7e, left two columns). However, wild-
type NK cells cultured with OMCP-mutIL-2 showed greater
STAT5 phosphorylation relative to cultures treated with wtIL-2.
Little STAT5 phosphorylation was evident in NKG2D / NK
cells treated with OMCP-mutIL-2 (Fig. 7e, right two columns).
Next NK cell-depleted splenocytes were treated with saturating
concentrations of IL-2Ra-blocking antibody (clone 3C7) prior to
recombination with NK cells. IL-2Ra blockade led to increased
STAT5 phosphorylation by wtIL-2, similar to that achieved by
OMCP-mutIL-2 (Fig. 7f). Collectively, these data demonstrate
that IL-2Ra expression by ‘competing’ stromal cells can limit
wtIL-2 mediated activation of NK cells. NKG2D-targeted,
IL-2Ra-binding impaired OMCP-mutIL-2 fusion protein,
however, can overcome these limitations even in the presence
of competing stromal cells.
OMCP-mutIL-2 offers superior control of malignancies in vivo.
NK cells form the primary barrier for expansion of some malig-
nancies, such as lymphoma and lung cancer16,32–34. To evaluate
lymphoma clearance we intravenously injected cytokine or fusion
protein-treated A/J mice with the A/J-derived CFSE-labelled YAC-1
lymphoblast cell line and evaluated their lungs 6 h later. Near
complete clearance of YAC-1 was evident in OMCP-mutIL-2
treated mice while a significant number of viable lymphoblasts
remained in wtIL-2, mutIL-2 and saline-treated mice (Fig. 8a and
Supplementary Data 1). Similarly bulk splenocytes of A/J mice
treated with OMCP-mutIL-2 lysed YAC-1 more efficiently than
those treated with wtIL-2, mutIL-2 or saline (Fig. 8b). Similar
results were obtained with LM-2 lung cancer targets
(Supplementary Fig. 6a).
To evaluate cytokine therapy in controlling lung cancer growth
we injected C57BL/6 mice in the flank with the highly aggressive
Lewis Lung Carcinoma (LLC) and five days later, when palpable
tumours were evident, treated them with either OMCP-mutIL-2,
wtIL-2, mutIL-2 or saline. Significantly decreased tumour growth
was evident after treatment with OMCP-mutIL-2 (Fig. 8c).
Splenocytes from OMCP-mutIL-2 treated mice also demon-
strated higher LLC cytotoxicity in vitro (Supplementary Fig. 6b).
Increased efficacy of OMCP-mutIL-2 immunotherapy disappears
in NKG2D / or NK1.1 depleted mice (Fig. 8d,e). In fact in
NKG2D / mice mutIL-2 increased the rate of LLC growth. To
further define the role of the adaptive immune system in
cytokine-mediated immunotherapy we next injected LLC into
C57BL/6Rag / mice, deficient in T, B and NKT cells. In this
mutant strain both wtIL-2 and OMCP-mutIL-2 were able to
mitigate tumour growth over mutIL-2 or saline-treated mice
(Fig. 8f). This data supports the model that OMCP-mutIL-2
mediated control of LLC growth can occur independent of T or
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NKT cells and confirms our in vitro data (Fig. 7c–f) that
‘competition’ for wtIL-2 from other lymphocytes limits NK cell
activation by wtIL-2.
Since intravenous injection of LLC results in pulmonary
metastases and rapid animal demise we next injected C57BL/6
mice with LLC i.v. and treated them with OMCP-mutIL-2,
wtIL-2, mutIL-2 or saline five days after tumour injection.
Significant prolongation of survival was evident in mice treated
with OMCP-mutIL-2 compared with all other conditions
(Fig. 8g). Collectively, our data suggest that OMCP-mediated
targeting of mutIL-2 to NKG2D expressing cells offers a safe and
efficacious form of immunotherapy for both solid and liquid
tumours in various strains of mice.
Discussion
Here we describe a unique approach for IL-2 immunotherapy
using a fusion protein targeting a mutant form of IL-2 to
NKG2D-expressing cells. We demonstrate that this approach
results in superior NK cell-mediated tumour immunotherapy
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with no adverse side effects associated with wild-type IL-2.
Several alternative strategies have been proposed to minimize the
untoward effects of IL-2 and preferentially activate cytotoxic
lymphocytes. One strategy has been to create mutants
with increased affinity for IL-2Rb to remove the preference for
IL-2Ra35,36. Our results suggest that competition with IL-2Ra-
expressing cells limits bioavailability of wtIL-2 to cytotoxic
lymphocytes. The IL-2Rb-enhanced IL-2 mutants would still bind
and activate Tregs and vascular endothelium, potentially limiting
their efficacy due to ‘off target’ IL-2 signalling.
Another potential way to overcome side effects involves
administration of anti-IL-2 antibodies that sterically inhibit
wtIL-2 binding to IL-2Ra1,37,38. Such treatment can extend
serum half-life29 due to the Fc region of the antibody and
potentially due to reduced competition for wtIL-2 from IL-2Ra-
expressing cells. However, IL-2Ra blockade could be incomplete
due to dissociation of antibody from IL-2. Additionally antibody-
IL-2 fusion proteins also have been designed to target IL-2 to
specific tumour antigens39,40. This approach could be limited by
tumour-mediated alteration of the targeted antigen under
selective pressure of the antibody-IL-2 fusion protein41.
IL-2 mutants with reduced affinity for IL-2Ra have also been
tested. Compared with wtIL-2 these mutants can be administered
in supratherapeutic doses without IL-2Ra-mediated capillary leak
or systemic toxicity42. While these mutants have excellent safety
profiles, they activate cytotoxic lymphocytes poorly (Fig. 4b,d)43.
Our approach combines these concepts to target a safe form of
IL-2 directly to cytotoxic lymphocytes, rather than tumours. This
is accomplished by replacing the normal targeting of IL-2 to
IL-2Ra with NKG2D. The combination of an IL-2Ra-deficient
IL-2 fused to a high affinity NKG2D-ligand improves upon
previous strategies by specifically expanding NK cells without any
apparent activation of Tregs or accumulation of extracellular fluid.
These findings offer the promise of a potentially safe and highly
efficacious form of IL-2.
One limitation in translating results from inbred lab animals to
humans is the natural diversity in cytokine reactivity and
threshold for lymphocyte activation. Previous studies have
demonstrated a correlation between ex vivo lymphocyte cyto-
toxicity and cancer immunity44. Therefore, any potential therapy
needs to account for a population that has differential levels of
cytotoxic lymphocyte activity and reactivity. For example, NK
cells from C57BL/6 mice are activated by wtIL-2 and high doses
of mutIL-2. In contrast, wtIL-2/anti-IL-2 antibody complexes
result in expansion of NK cells in A/J but not C57BL/6 mice
(Fig. 4b versus d). Such variations highlight the limitations of
translating results derived from a single strain of mice to
immunologically diverse humans. Of note, OMCP-mutIL-2
expanded NK cells in both strains of mice indicating that this
therapy could be efficacious in populations with diverse NK
function and reactivity.
As OMCP has been described as a competitive antagonist of
NKG2D activation its use may be construed as counterproductive
for tumour immunotherapy14,15. Nevertheless, natural cytoto-
xicity and tumour clearance were augmented in OMCP-mutIL-2-
treated mice even in the presence of established tumours. NKG2D
signal transduction in vitro was relatively preserved as well
(Supplementary Fig. 4e). This suggests minimal or transient
NKG2D receptor occupancy and preservation of its signalling
capacity. Alternatively, shed NKG2D ligands may promote
tumour immunity through reversal of NK desensitization
imposed by chronic agonist engagement45. It is thus possible
that within the tumour bed such competitive antagonism plays a
paradoxical role in NK activation. OMCP thus presents an ideal
‘targeting vector’ due to its high affinity and long half-life of
binding to NKG2D.
Immunogenicity can be an obstacle to successful therapy with
cytokine mutants. Anti-protein antibodies can neutralize the
cytokine effect on repeat administration and T cell-specific
antigens may induce cellular immunity as well. For this reason we
have chosen a virally encoded delivery system which has co-
existed and co-evolved with man for immunoevasion14. While
previous clinical trials of IL-2 mutants did result in the detection
of anti-mutant IL-2 antibodies in some patients, no adverse side
effects were associated with this immune response46. Nevertheless
future work may need to be done to identify and modify any
immunogenic determinants in OMCP-mutIL-2 prior to
translation to clinical applications in man.
While NK cells from two separate strains of mice were
activated by OMCP-mutIL-2 we did not detect global expansion
or activation of T cells in vivo, although CD8þ T cells were
activated by higher concentrations in vitro (Fig. 2c) or after the
addition of a T cell receptor agonist (Supplementary Fig. 2c).
NKT cells were activated in vivo by OMCP-mutIL-2, albeit to a
lesser extent then NK cells (Supplementary Fig. 4b,d). Such effects
could be the result of differences in thresholds for cytokine
activation of different lymphocyte subsets in the absence of
additional activating receptor stimulation. Alternatively it is
possible that NK cell are constitutively activated through
endogenously present stress ligands on dead or dying cells while
T cells receive little receptor stimulation in the absence of
exogenously administered agonists. Based on our phenotypic
findings of selective NK expansion we focused on immunother-
apy for lung cancer and lymphoma, whose growth is restricted
primarily by NK cells16,33,34,47. However NKG2D-targeted
delivery of immunostimulatory cytokines may lead to the
expansion and/or activation of both NK and antigen-specific
CD8þ T cells and NKT cells in the presence of appropriate T cell
receptor stimulation. Future work will focus on tumour models
containing tumour-associated antigens in order to study the
interplay of the innate and adaptive immune system after targeted
delivery of IL-2.
Methods
Cytokine and construct generation. The sequences encoding human IL-2 (1–133;
C125S) and mutant IL2 (1–133; R38A, F42K, C125S) (GTGSSGSSDYKDDDDKH
HHHHHHHGSSGSSAPTSSSTKK TQLQLEHLLLDLQMILNGINNYKNPKLA
MLTKKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNIN
VIVLELKGSETTFMCEYADETATIVEFLNRWITFSQSIISTLT) were cloned into
the pFM1.2R(ref. 41) with an N-terminal FLAG/hexahistidine tag. The chimeric
OMCP-mutIL-2 molecule comprises the full-length OMCP (1–152) coding
sequence cloned in frame with mutant IL-2 (1–133; R38A, F42k, C125S) joined by
a glycine/serine linker (OMCP-mIL2: HKLAFNFNLEINGSDTHSTVDVYLDD
SQIITFDGKDIRPTIPFMIGDEIFLPFYKNVFSEFFSLFRRVPTSTPYEDLTYFYE
CDYTDNKSTFDQFYLYNGEEYTVKTQEATNKNMWLTTSEFRLKKWFDGE
DCIMHLRSLVRKMEDSKRNTGGTGSSGSSDYKDDDDKHHHHHHHHGSSG
SSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTAMLTKKFYMPKK
ATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTF
MCEYADETATIVEFLNRWITFSQSIISTLT) cloned into the pFM1.2R vector.
Proteins were expressed by transient transfection into FreeStyle 293-F cells
(Life Technologies). Supernatant was recovered at 72 and 144 h post-transfection.
Supernatants were supplemented with 5mM imidazole and 0.02% sodium azide
and purified by nickel-nitrilotriacetic acid (Ni-NTA) chromatography (Gold-Bio).
Purified proteins were buffer exchanged into phosphate-buffered saline and flash
frozen in liquid nitrogen. Equivalent in vitro and in vivo activity was documented
for wild-type IL-2 generated in house and Teceleukin (Tecint) available from
the NCI repository (Frederick National Laboratory for Cancer Research). Thus,
for some experiments these two preparations of IL-2 were used interchangeably.
Wild-type IL-2 has a specific activity of 15 106 IUmg 1 (ref. 48). Thus,
based on the molecular weight of 15.5 kDa a 4.4 mM solution is equivalent to
1,000 IU ml 1. Based on this calculation all cytokines and construct were
administered on a molar basis with 1 ml of 4.4 mM solution defined as 1,000 IU
equivalents (IUe from here on). Such a system allows for equimolar comparison
between IL-2, mutIL-2 and OMCP-mutIL-2 despite difference in molecular weight.
Animals. Male A/J, C57BL/6J, C57BL/6CD45.1þ and C57BL/6Rag1 / mice 8–12
weeks of age were purchased from The Jackson Laboratory (Bar Harbour, Maine).
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NKG2D / mice on the B6 background were kindly provided by Wayne
Yokoyama (Howard Hughes Institute of Medicine at Washington University in St
Louis) and bred in house. Animals were housed in a barrier facility in air-filtered
cages and allowed free access to food and water. For some experiments A/J mice
were treated with depleting concentrations of anti-Asialo-GM1 (50 ml day  2;
25ml day  1) or control rabbit IgG (Wako Chemical Company). Animal proce-
dures were approved by the animal studies committee of Washington University
School of Medicine, St Louis, MO.
Tissue harvest and in vitro cultures. Single cell suspensions of splenocytes were
obtained by crushing whole spleens through 70 mm cell strainers prior to RBC lysis
by ACK buffer (Lonza, Walkersville, MD) and re-filtration through a 40 mm filter.
Lungs were digested for 90min at 37 C in 1mgml 1 collagenase II (Fisher
Scientific), and 5Uml 1 DNase I (Sigma-Aldridge) prior to processing in an
identical fashion to spleens.
For in vitro cultures splenocytes from either A/J, B6, or NKG2D / mice
were extracted in a sterile fashion and seeded in 12-well plates in complete media
(RPMI 1640 supplemented with 10% FBS, 100Uml 1 Penicillin and Strepto-
mycin, 2mM L-glutamine and 50 mM 2-Mercaptoethanol) at 5 million cells per ml
per well. The cells were treated with increasing doses of human recombinant IL-2,
mutIL-2, OMCP-mutIL-2, or OMCP for 36 h as described in the manuscript. For
some experiments bulk splenocytes were labelled with CFSE and cultured in
1000 IUeml 1 of cytokine for 5 days prior to flow cytometric analysis. For NK
isolation experiments bulk splenocytes were processed using either the NK cell
isolation kit II or CD49b (DX5) positive magnetic bead selection (both from
Miltenyi Biotech). For STAT5 phosphorylation experiments isolated NK cells were
stimulated in increasing concentrations of IL-2 or construct at 100,000 cells
per 500ml for 15min. For experiments evaluating the interaction of NK cells
with splenic stroma DX5 positively selected NK cells were labelled with CFSE
(for identification after fixation and permeabilization) and recombined with
NK-depleted stromal cells at a 5%/95% NK/stromal cell ratio. As described in the
manuscript for some studies NKG2D / NK cells were combined with wild-type
splenic stromal cells. For other experiments NK-depleted splenocytes from
wild-type B6 mice were treated with saturating concentrations of anti-IL-2a
blocking antibody (clone 3C7) or isotype control (both from Biolegend) prior to
recombining with NK cells. For such competitive STAT5 phosphorylation
experiments 100,000 cells (including 5% CFSE-labelled NK cells) were resuspended
into 2 ml complete media containing 1,000 IUml 1 of either wtIL2, mutIL-2 or
OMCP-mut-IL-2 (freshly prepared and pre-warmed). The cells were then
incubated at 37 C for 15min.
Human PBMC were collected under IRB approved protocol at Washington
University in St Louis. Informed consent was obtained from all volunteers donating
blood. For non-antigen specific cytokine driven expansion and activation, freshly
isolated PBMC were co-cultured for 72 h with appropriate concentration of
cytokines and lymphocyte phenotype determined flow cytometrically as described
in each figure. For antigen-specific stimulation, PBMC from CMV-seropositive
donors were cultured with pp65 peptide and the indicated concentration of
cytokine. Two weeks after culture initiation, cells were harvested and stained with
anti-CD8 Ab and HLA-A*0201/CMV pp65 peptide tetramers and analysed by flow
cytometry.
Flow cytometry. All flow cytometric analysis was performed using saturating
concentrations of fluorochrome-conjugated antibodies at 4 C in FACS buffer
consisting of PBS with 2% FBS and 0.4% EDTA. All antibodies were anti-mouse
and purchased from BD Bioscience or eBioscience. Unless otherwise indicated in
the antibody data sheet all staining was performed by adding 1 ml of the fluor-
ochrome-conjugated antibody to 1–2 106 splenocytes and stained at 4 C for
30–45min in 100ml FACS buffer consisting of phosphate buffered saline with
5% fetal calf serum. Excess antibody was removed by two consecutive washings.
Antibodies used for this study consisted of anti-CD4 (clones GK1.5 or RM4–5),
anti-CD8 (clone 53-6.7), anti-CD278 (ICOS) (clone: 7E.17G9), anti-CD25 (clone
PC61), anti-KLRG1 (clone 2F1), CD49b (Integrin alpha 2) (clone DX5), anti-CD3e
(clone 145-2C11), anti-CD45 (clone 30-F11), anti-CD69 PE (clone H1.2F3),
anti-GITR (clone DTA-1), anti-Foxp3 (clone: FJK-16s) and Anti-Stat5 (clone
47/Stat5; pY694). Antibodies were conjugated to either FITC, PE, PerCP-Cy5.5,
PE-Cyanine7, APC, APC-eFluor 780, eFluor 450 or Alexa Fluor 647. Human
peripheral blood leucocyte analysis was carried out similar to murine splenocyte
data with some modifications. Specifically perforin staining was carried out using
the purified mouse anti-human perforin (clone dG9) from BD Bioscience. After
surface staining the leucocytes were fixed and permeabilized with BD fixation and
permeabilization solution. The cells were stained with fluorochrome-conjugated
anti- perforin or isotype control per manufacturer instructions. Additional human
antibodies consisted of mouse anti-human CD56 (clone MY31), anti-CD3
(clone SK7), anti-CD8 (SK1) and anti-CD4 (SK3) from BD Bioscience.
Phospho-STAT5 evaluation was performed by paraformaldehyde fixation,
methanol permeabilization, followed by staining with AlexaFluor488-conjugated
Anti-Stat5 (pY694) (BD Pharmingen; clone 612599). To accomplish this isolated
NK cells were combined with NK-depleted splenic stromal cells and fixed in 2%
paraformaldehyde at 37 C for 10min after IL-2 stimulation for 15min at 37 C.
The cells were then washed once with ice-cold PBS and permeabilized by adding
0.5ml per tube of 90% methanol on ice for 1 h. Methanol was removed and the
cells were washed once with ice-cold PBS (to wash away the excess methanol), and
stained for 1 h with anti-Stat5 (pY694) antibody at room temperature followed by
one wash in PBS containing 0.5% fetal calf serum and 0.4% EDTA.
For analysis of construct and cytokine binding to lymphocytes recombinant
wtIL-2, mutIL-2 and OMCP-mutIL-2 were biotin labelled using EZ-Link
NHS-PEG4-Biotin (Thermo Fischer Scientific) following manufacturer’s
instruction. Mouse spleen cells were first incubated with FACS buffer or unlabelled
OMCP at 0.8 mM followed by staining with each of the biotin-labelled IL-2 proteins
at 0.15 mM and a mixture of fluorescence conjugated antibodies in Fc block
in two steps. Finally the cells were stained with PE-streptavidin. All staining was
carried out on ice with 30min incubation for each step. Stained samples were
analysed by flow cytometry using BD LSRFORTESSA X-20 and the data were
analysed with FlowJo software (Tree Star). NK cells were defined as viable,
NK1.1þCD3CD19 .
Western blot analysis of signalling pathways. Murine NK cells were purified
from C57BL/6 male spleens immediately prior to the experiment according to the
procedure described elsewhere in this manuscript. KY1 (murine) cell line was
maintained in RPMI-1640 medium without serum and IL2 for 4 h prior to the
experiment. Hamster anti-mouse NKG2D/CD314 clone A10 (manufactured in
house) were immobilized in PBS on 6-well tissue culture plates (TPP, Midwest
Scientific, Valley Park, MO) either overnight at 4 C or for 3 h at 37 C. The
wells were washed once with PBS followed by the addition of 1000 IUeml 1 of
OMCP-mutIL-2, wtIL-2, and mutIL-2 and 2mM sodium pervanadate (Sigma, St
Louis, MO) to the appropriate wells, except the NKG2D well. Next, 5 106 KY1.1
cells or 1 106 murine NK cells were added to the wells and plates incubated at
37 C for 5min. The cells were lysed in situ for 30min at 4 C by the addition of
10 cell lysis buffer containing 20mM Tris-HCl (pH 7.5), 150mM NaCl 1mM
Na2EDTA, 1mM EGTA, 1% Triton X-100, and protease inhibitors cocktail. The
resulting cell lysates were cleared by centrifugation at 14,000 r.p.m. For JAK1
phosphorylation experiments lysates were immunoprecipitated overnight with
anti-JAK1 clone A-9 monoclonal antibody (Santa Cruz Biotechnology, Dallas, TX).
Bulk lysates from freshly isolated NK cells were evaluated for phospho-Vav by the
anti-p-Vav (Tyr 174) rabbit polyclonal antibody (Santa Cruz Biotechnology, Dallas,
TX) without co-immunoprecipitation. The immune complexes were adsorbed
concomitantly with 20ml Protein G Plus agarose (Santa Cruz Biotechnology,
Dallas, TX). After three washes with cell lysis buffer, the proteins were resolved on
a 10% Tris-Glycine SDS–polyacrylamide gel electrophoresis (SDS-PAGE) gel
(Bio-Rad, Hercules, CA) and transferred to an Immobilon-P polyvinylidene
fluoride (PVDF) membrane. Next, the membranes were blocked with 3% BSA
in PBS with 0.1% Tween-20 for 1 h at 20 C. Phoshoproteins were then detected
with either rabbit anti-pVav or goat anti-pJAK1 antibodies (both from Santa Cruz
Biotechnology, Dallas, TX) followed by the appropriate secondary antibodies
conjugated to horseradish peroxidase. The horseradish peroxidase activity was
detected with Pierce enhanced chemiluminescence substrate (ThermoFisher
Scientific, Waltham, MA) according to the manufacturer’s instructions. The
chemiluminescence signal was acquired with the ChemiDoc-MP Immaging System
and analysed with the Image Lab 5.1 software application (both from Bio-Rad,
Hercules, CA). Images presented throughout the manuscript have been cropped
for presentation. Full size images are presented in Supplementary Fig. 7.
LacZ assay. The BWZ.36 thymoma cell line, in which the expression of a
transfected heterologous Escherishia coli B-galactosidase (lacZ) gene is controlled
by the nuclear factor in activated T cells (NFAT), was generously provided by
Dr Nilabh Shastri (University of California, Berkeley). The mouse NKG2D short
isoform and DAP12 (wildtype or Y2F mutant) were transduced into BWZ.36 cells
by retroviral vector pMX.IRES.Bs and pMIG, respectively as reporter cells for
NKG2D signalling. 4–5 104 per well of these cells in 100 ml complete RPMI1640
were cultured in the presence of 1000Uml 1 wtIL2, mutIL2 or OMCP-mutIL2
for 16 h at 37 C before lysed by Z buffer (9mM MgCl2, 0.125% NP40 in PBS)
containing 150 mM chlorophenol red-b-D-galactopyranoside, a substrate of lacZ.
After a 6 h incubation at 37 C absorbance of each well was measured by 96-well
plate reader at OD595 nm. Cells cultured with PMA (10 ngml 1) and ionomycin
(0.2 mgml 1) served as a positive control for NFAT-lacZ activation in each
cell line, while cells cultured in the wells pre-coated with anti-NKG2D antibodies
(A10, at 12 mgml 1) served as a control for NKG2D signalling.
In vitro cytotoxicity. 51Chromium release was conducted by incubating the target
cells with 100 mCi sodium 51chromate (PerkinElmer) for 1 h. Bulk splenocytes were
used as effector cells and incubated with targets at defined effector:target ratios for
4 h at 37 C in round bottom 96 well plates. Specific lysis was expressed as
(experimental release-spontaneous release)/(maximum release-spontaneous
release) 100% with 0% specific lysis as lowest expressed value.
In vitro Treg suppression. CD90.2þ T lymphocytes from ‘responder’ CD45.1þ
C57BL/6 mice were isolated from bulk splenocytes using magnetic beads (Miltenyi
Biotech), labelled with CFSE, and combined with CD90.2-depleted splenocytes
from C57BL/6CD45.2þ congenic mice at a 1:1 ratio in U bottom 96 well plates.
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Anti-CD3 Ab (clone 145-2C11; BD Pharmingen) at 3 mgml 1 final concentration
was added to the cultures. Tregs from CD45.2þ congenic mice, expressing GFP
on a Foxp3 promoter, were flow-cytometrically sorted from splenocytes and
lymphocytes after cytokine administration as described in the text. Tregs were added
to the co-cultures in a 1:1, 0.5:1, 0.25:1, 0.125:1 and 0:1 ratio in 200ml final
volumes of media. Seventy hours later proliferation of responder T cells was
determined flow-cytometrically based on dilution of CFSE in CD45.1þCD45.2 T
lymphocytes.
In vivo cytokine injections. For in vivo experiments the mice received intraper-
itoneal injections of cytokines in 200ml volume. Dilutions were made from a stock
solution of 44mm, which is equivalent to 10,000 IUe ml 1. Thus for A/J mice,
which received ten equal doses of 20,000 IUe per dose for a total of 200,000 IUe
over the course of five days, 2 ml were resuspended in 198ml of saline for injection.
For C57BL/6 mice, which received 10 equal doses of 75,000 IUe per dose for a total
of 750,000 IUe over the course of five days, 7.5 ml were resuspended in 192.5 ml of
saline for injection. All cytokines were given in 10 equal doses twice a day (BID)
over a period of five days to total the cytokine described in the results. As described
above all cytokines were normalized to IUe on a molar basis. For select experi-
ments, the mice were then killed on day 6 and organs were fixed in 10% buffered
formalin for histological analyses. For other experiments splenocyte and lung
lymphocyte populations were analysed flow cytometrically. For all the in vivo
cytokine treatment experiments, animals were weighted (daily or every other day)
and expressed as % change from start of cytokine therapy.
For evaluation of serum concentration wtIL-2, mutIL-2 or OMCP-mutIL-2
were labelled with Alexa Fluor 647 (LifeTechnologies Inc.) according to
manufacturer instructions. Serum was collected at times specified and
concentration of cytokine determined fluoroscopically according to a standard
curve.
In vivo tumour studies. Lewis lung carcinoma (LLC) cells were subcutaneously
injected into C57BL/6, C57BL/6NKG2D / or C57BL/6Rag1 / mice at 1 105
cells per mouse in 100ml of sterile saline. Once visible tumours were evident, day 5
post-injection, a five-day course of cytokine treatment (given in BID doses) was
started as described above. Measurement of cross sectional tumour diameter was
performed using calipers and tumour volume estimated as 4/3pr3. The mice were
killed on day 24 post injection. Animals were monitored every 2 days, starting 6
days after injection and tumour size recorded. Animals were killed if tumours
measured 420mm in any direction, or if they showed signs of distress or loss of
415% of their body weight. Supplementary Data 1 shows the raw data for tumour
measurements shown in Fig. 8c. One tumour in the IL-2, mutIL-2 and OMCP-
mutIL-2 from experiment shown in Fig. 8c, developed a skin ulcer within three
weeks of injection and was excluded from final analysis. Permission was obtained
from the veterinarian, on an individual basis, to maintain animals with skin ulcers
over tumours. Once any animal in any group was recorded as having a tumour
measuring 420mm in diameter, all animals were killed and the study terminated.
For NK cell depletion, mice were treated with anti-NK1.1 antibody (clone PK136)
or mouse IgG isotype control (both from BioXcell) at 500mg day  2, 250 mg day
 1 and 250 mg weekly for the duration of the experiment. For lymphoma clear-
ance experiments A/J mice were treated with ten doses of cytokine over a period of
5 days as described above and on day 6 injected intravenously with YAC-1 cells
that were labelled with CFSE at 5 106 cells per /mouse. Mice were killed 4 h later,
lungs were digested and viability of YAC-1 determined by forward and side scatter
analysis of CFSEþ cells.
Statistics. Comparison of splenic and lymphocytes between various cytokine
treatment conditions was performed by unpaired T-test with Welch’s correction to
account for unequal variance or unequal sample size. Tumour growth between
different cytokine conditions was compared by multiple unpaired-T tests
performed between various conditions at various time points using the
Sidak–Bonferroni correction. Fold change in STAT5 phosphorylation was
evaluated by unpaired T-test with Welch’s correction in a similar fashion. In vitro
lymphocyte activation and proliferation was performed by paired T-test across the
same experimental conditions. Comparison of multiple groups performed by
analysis of variance (ANOVA) where indicated.
Data availability. The data that support the findings of this study are contained
within the Article or Supplementary Files, or available from the authors on request.
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